Bayesian Capital Management LP Acquires New Shares in Liquidia Co. (NASDAQ:LQDA)

Bayesian Capital Management LP bought a new position in shares of Liquidia Co. (NASDAQ:LQDA) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 13,900 shares of the company’s stock, valued at approximately $163,000.

Other large investors also recently modified their holdings of the company. Acuta Capital Partners LLC grew its position in shares of Liquidia by 87.4% in the 4th quarter. Acuta Capital Partners LLC now owns 137,709 shares of the company’s stock valued at $1,619,000 after purchasing an additional 64,209 shares during the period. Northern Trust Corp boosted its holdings in shares of Liquidia by 19.5% in the fourth quarter. Northern Trust Corp now owns 589,921 shares of the company’s stock valued at $6,937,000 after buying an additional 96,381 shares during the period. Tudor Investment Corp ET AL bought a new stake in shares of Liquidia during the fourth quarter worth $454,000. Aquatic Capital Management LLC acquired a new stake in shares of Liquidia during the fourth quarter worth $866,000. Finally, Adage Capital Partners GP L.L.C. bought a new stake in Liquidia in the 4th quarter valued at $992,000. 64.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on LQDA shares. Scotiabank restated an “outperform” rating on shares of Liquidia in a report on Monday. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research note on Thursday, March 20th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price target on shares of Liquidia in a research note on Thursday, April 10th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $26.88.

Insider Buying and Selling at Liquidia

In other Liquidia news, General Counsel Russell Schundler sold 5,964 shares of the stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $80,931.48. Following the transaction, the general counsel now directly owns 570,301 shares of the company’s stock, valued at $7,738,984.57. This represents a 1.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Roger Jeffs sold 14,130 shares of the business’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $191,744.10. Following the sale, the chief executive officer now owns 1,006,420 shares of the company’s stock, valued at approximately $13,657,119.40. This represents a 1.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,138 shares of company stock worth $450,233 over the last 90 days. Company insiders own 26.50% of the company’s stock.

Liquidia Trading Down 1.2 %

NASDAQ:LQDA opened at $15.35 on Friday. The firm has a fifty day simple moving average of $14.25 and a 200 day simple moving average of $13.12. Liquidia Co. has a 1-year low of $8.26 and a 1-year high of $16.81. The stock has a market capitalization of $1.31 billion, a PE ratio of -9.42 and a beta of 0.24.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. On average, equities analysts predict that Liquidia Co. will post -1.51 earnings per share for the current fiscal year.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).